BCIQ Profiles

Company Profile Report

Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment

Read the full 260 word article

How to gain access

Continue reading with a
two-week free trial.